- <![CDATA[HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response]]><![CDATA[HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.]]>onclive · 2mo ago↗ source
- <![CDATA[Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)]]><![CDATA[Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.]]>onclive · 2mo ago↗ source
- <![CDATA[Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss]]><![CDATA[How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.]]>